Ad26 Mos HIV trivalent vaccine - Janssen Vaccines and Prevention

Drug Profile

Ad26 Mos HIV trivalent vaccine - Janssen Vaccines and Prevention

Alternative Names: Ad26 Mos HIV; Ad26 Mos HIV + clade C gp140; Ad26 mosaic vector + gp140; Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos.HIV + gp140; Adenovirus-serotype-26-Mosaic-HIV-vaccine; Adenovirus-serotype-26-Mosaic-HIV-vaccine + Clade C glycoprotein 140

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Crucell Holland
  • Developer Beth Israel Deaconess Medical Center; International AIDS Vaccine Initiative; Janssen Vaccines and Prevention B.V; U.S. Military HIV Research Program
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 01 Sep 2016 Phase-I/II clinical trials in HIV infections (Combination therapy, Treatment-experienced) in Thailand (IM) (NCT02919306)
  • 01 Jul 2016 Phase-II clinical trials in HIV infections (Prevention) in USA (IM) (NCT02788045)
  • 27 May 2016 Crucell Holland plans a phase I/IIa trial for HIV infections (Prevention) in USA and Rwanda (IM) (NCT02788045)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top